NASDAQ : TCRT
Alaunos Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.95 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 4.95M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.95M |
| Enterprise Value | 4.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.54M |
| Shares Outstanding | 2.54M |
| Shares Change (YoY) | +43.66% |
| Shares Change (QoQ) | +24.81% |
| Owned by Insiders (%) | 25.55% |
| Owned by Institutions (%) | 6.01% |
| Float | 1.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,651.31 |
| Forward PS | n/a |
| PB Ratio | 7.44 |
| P/TBV Ratio | 7.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1,609.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.77 |
| Quick Ratio | 0.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -185.95% |
| Return on Assets (ROA) | -81.13% |
| Return on Invested Capital (ROIC) | -117.58% |
| Return on Capital Employed (ROCE) | -622.24% |
| Weighted Average Cost of Capital (WACC) | -0.53% |
| Revenue Per Employee | $3,000 |
| Profits Per Employee | -$4.12M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.87 |
| 52-Week Price Change | -28.31% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 2.33 |
| Relative Strength Index (RSI) | 50.03 |
| Average Volume (20 Days) | 21,595,814 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 818,602 |
| Short Previous Month | 9,736 |
| Short % of Shares Out | 32.22% |
| Short % of Float | 68.01% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3,000 |
| Gross Profit | -1.64M |
| Operating Income | -4.06M |
| Pretax Income | -4.01M |
| Net Income | -4.12M |
| EBITDA | -4.03M |
| EBIT | -4.06M |
| Loss Per Share | -$1.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 124,000 |
| Total Debt | n/a |
| Net Cash | 124,000 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 652,000 |
| Book Value Per Share | 0.26 |
| Working Capital | -198,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.73M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | 70,000 |
| Free Cash Flow | -2.83M |
| FCF Per Share | -$1.11 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -135,233.33% |
| Pretax Margin | -133,666.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.66% |
| Shareholder Yield | -43.66% |
| Earnings Yield | -90.69% |
| FCF Yield | -57.03% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -860.17 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |